Cargando…

Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population

We retrospectively evaluated off-label use of dalbavancin as secondary therapy in 32 patients with serious Staphylococcus aureus infections (endocarditis, osteomyelitis, septic thrombophlebitis, epidural infection) who were also persons who use drugs. The majority of patients (56%) had a clinical re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bryson-Cahn, Chloe, Beieler, Alison M, Chan, Jeannie D, Harrington, Robert D, Dhanireddy, Shireesha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388764/ https://www.ncbi.nlm.nih.gov/pubmed/30838225 http://dx.doi.org/10.1093/ofid/ofz028

Ejemplares similares

A Little Bit of Dalba Goes a Long Way: Dalbavancin Use in a Vulnerable Patient Population
por: Bryson-Cahn, Chloe, et al.
Publicado: (2017)

Evaluation of Bundled Interventions for Patients With Opioid Use Disorder Experiencing Homelessness Receiving Extended Antibiotics for Severe Infection
por: Beieler, Alison M, et al.
Publicado: (2021)

616. Patients Experiencing Homelessness and Opioid Use Disorder with Infectious Complications Treated with OPAT at Medical Respite: Evaluation of Retention in Care at 30 days and Role of Addictions Consultation
por: Beieler, Alison M, et al.
Publicado: (2020)

In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR) Staphylococcus aureus Isolates
por: Bongiorno, Dafne, et al.
Publicado: (2020)

Perspectives on the Use of Outpatient Parenteral Antibiotic Therapy for People who Inject Drugs: Results From an Online Survey of Infectious Diseases Clinicians
por: Solomon, Daniel A, et al.
Publicado: (2023)

628. The Role of the Advanced Practice Provider in Infectious Disease: Opportunities for Growth
por: Yoke, Leah H, et al.
Publicado: (2020)

617. Physician Perspective: Utilization of Advanced Practice Providers (APPs) in the ID Workforce
por: Beieler, Alison M, et al.
Publicado: (2020)

325. Neurosyphilis Management in the Post-Procaine Penicillin Era
por: Cannon, Chase, et al.
Publicado: (2018)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

Antibiotic prescribing patterns for bacterial superinfection of mpox: A retrospective cohort study in an urban center
por: Simmons, William F., et al.
Publicado: (2023)

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
por: Barber, Katie E., et al.
Publicado: (2017)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus
por: Jacob, Benjamin, et al.
Publicado: (2021)

Dalbavancin Boosts the Ability of Neutrophils to Fight Methicillin-Resistant Staphylococcus aureus
por: Scutera, Sara, et al.
Publicado: (2023)

Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
por: Knafl, D., et al.
Publicado: (2016)

Advanced practice providers in the infectious disease workforce: A nationwide utilization survey
por: Beieler, Alison M., et al.
Publicado: (2021)

965. Advanced Practice Providers in Infectious Disease: Educational Needs and Opportunities
por: Yoke, Leah H, et al.
Publicado: (2021)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus
por: Hoyt, Aaron K., et al.
Publicado: (2023)

744. Infectious Diseases Providers Perspectives Around the Use of Outpatient Parenteral Antibiotic Therapy (OPAT) for Persons Who Inject Drugs (PWID), US, 2022
por: Solomon, Daniel A, et al.
Publicado: (2022)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Building HIV Workforce Capacity Through a Residency Pathway: Outcomes and Challenges
por: Budak, Jehan Z, et al.
Publicado: (2018)

Elevated Spontaneous Interferon-γ Secretion in Human Immunodeficiency Virus-Infected Persons
por: Sparks, Rachel, et al.
Publicado: (2017)

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model
por: Kussmann, Manuel, et al.
Publicado: (2018)

Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report
por: Otero, Judith Álvarez, et al.
Publicado: (2019)

Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy
por: Vazquez Deida, Axel A, et al.
Publicado: (2020)

Partial-Oral Antibiotic Therapy for Bone and Joint Infections in People With Recent Injection Drug Use
por: Yang, Wei-Teng, et al.
Publicado: (2023)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

Use of dalbavancin in infective endocarditis: a case series
por: Guleri, Achyut, et al.
Publicado: (2021)

Electronic Consults for Infectious Diseases in a United States Multisite Academic Health System
por: Wood, Brian R, et al.
Publicado: (2020)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin
por: Kebriaei, Razieh, et al.
Publicado: (2023)

How to disagree better: utilizing advocacy-inquiry techniques to improve communication and spur behavior change
por: Castillo, Alyssa Y., et al.
Publicado: (2023)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2020)

THE PLASMA MEMBRANE OF STAPHYLOCOCCUS AUREUS
por: Suganuma, Atsushi
Publicado: (1961)

Characterization of Secondary Bacterial Infections and Antibiotic Use in Mechanically Ventilated Patients With COVID-19 Induced Acute Respiratory Distress Syndrome
por: Risa, Erik, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_teb0b8351m32tbja1kuvjuh66j